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Introduction
Functional models of ligand binding and efficacy at receptors such as ligand-gated ion channels incorporate the proposition that agonism is a feature of ligands that bind with higher affinity to active receptors relative to inactive receptors, and therefore shift the inactive⇔active equilibrium toward active (Auerbach, 2012; Buxton, 2006; Colquhoun, 1998; Kenakin, 2004) .
This concept applies to both orthosteric and allosteric agonists. Consequently, the apparent affinity of an agonist for receptors in assays of both function and ligand-binding depends on its intrinsic efficacy (Colquhoun, 1998) . Monod-Wyman-Changeux (MWC) allosteric models of receptor function define agonist efficacy as the ratio of affinities for active versus inactive states (Changeux, 2012) , and provide a framework for estimating agonist affinity and intrinsic efficacy parameters in ligand-gated ion channels, which are the only receptors where signals directly proportional to receptor activity (voltage-clamped currents) can be readily obtained (Auerbach, 2012; Chang and Weiss, 1999; Galzi et al., 1996; Rüsch et al., 2012; Rüsch et al., 2004) .
Nonetheless, experimental validation of model-derived estimates for agonist binding affinities at inactive receptors is confounded by agonist induction of receptor activation, which simultaneously alters agonist-receptor interactions. One rare example of this achievement used complex rapid mixing and fluorescent detection of the nicotinic agonist dansyl-C6-choline binding to Torpedo nicotinic acetylcholine receptors (Raines and Krishnan, 1998) . In the present study, we identified a mutant γ-aminobutyric acid type A (GABA A ) receptor with unique functional characteristics that enable experimental determination of binding site occupancy for an allosteric agonist/modulator, etomidate, in both inactive and active receptors.
Synaptic GABA A receptors are pentameric membrane complexes typically formed from two α, two β, and one γ subunit symmetrically surrounding a chloride-conducting ion channel (Olsen and Sieghart, 2008) . Each subunit contains a large N-terminal extracellular domain and four transmembrane domains (M1 to M4), with M2 domains from each subunit surrounding the This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on March 22, 2013 as DOI: 10.1124 at ASPET Journals on July 5, 2017 molpharm.aspetjournals.org Downloaded from ion channel. The M1, M3, and M4 domains form an outer ring of helical domains between the M2 domains and membrane lipids. Two GABA sites per receptor are formed at the extracellular interfaces between α and β subunits.
The allosteric agonist used in this study is etomidate, a potent general anesthetic that acts by modulating GABA A receptors. In wild-type α1β2γ2L GABA A receptors, low etomidate concentrations enhance GABA-mediated receptor activation, while high etomidate concentrations (> 10 μM) directly activate receptors in the absence of GABA. The gating effects of both GABA and etomidate are quantitatively described by a Monod-Wyman-Changeux (MWC) two-state allosteric co-agonist mechanism with two equivalent sites for etomidate (Guitchounts et al., 2012; Rüsch et al., 2004) . The etomidate sites are located within transmembrane interfaces between α-M1 and β-M3 domains, based on labeling with photoreactive etomidate derivatives (Chiara et al., 2011; Li et al., 2006) .
The receptors we used in this study incorporate cysteine mutations at one photolabeled residue in etomidate binding sites: β2M286. Studies in rat α1β2M286Cγ2L GABA A receptors demonstrate that the β2M286C sulfhydryl is covalently modified by a water-soluble reagent, pchoromercuribenzene sulfonate (pCMBS), and that GABA activation accelerates this reaction (Bali and Akabas, 2004; Bali and Akabas, 2012) . We conducted a detailed electrophysiological analysis of heterologously expressed human α1β2M286Cγ2L GABA A receptor function, which revealed the absence of etomidate agonism. However, etomidate modulation of GABAmediated activation is maintained in the mutant receptors, albeit weaker than in wild-type.
These properties allowed us to experimentally determine etomidate affinity in both inactive and GABA-activated mutant channels, based on etomidate-dependent inhibition of covalent bond formation between β2M286C and pCMBS. By tracking the electrophysiological effects of this reaction in mutant receptors, we quantified the apparent rate of pCMBS-β2M286C bond formation in both inactive (no GABA) and GABA-activated receptors, while varying etomidate MOL #84558 using two microelectrode voltage clamp electrophysiology, as previously described (Rüsch et al., 2004) . GABA pulses were from 5 to 20s, depending on the concentration of GABA used and the time to peak current. Normalizing GABA responses at maximal GABA (2-10 mM), were recorded every 2 nd or 3 rd sweep. Oocyte currents were low-pass filtered at 1 kHz (Model OC-725B, Warner Instruments, Hamden, CT) and digitized at 2 kHz using commercial digitizer hardware (Digidata 1200, Molecular Devices, Sunnyvale, CA) and software (Clampex 7, Molecular Devices) for off-line analysis.
Cysteine Modification with pCMBS and Etomidate Protection in Xenopus Oocytes. The pCMBS concentrations were chosen so that control modification (with or without 2 mM GABA) appeared complete after 40-60 s of pCMBS exposure. In modification experiments, GABA responses to both low GABA (30 μM, approx. EC 5 ) and high GABA (1-2 mM) were measured before and after each exposure to pCMBS ± GABA. Additional control modification experiments included 2 μM alphaxalone with GABA in order to maximize the fraction of activated receptors.
In protection experiments, etomidate was present throughout the experiment, and was thus added to background buffer, pCMBS solutions, and GABA solutions. Because etomidate enhances GABA responses in the mutant receptors, functional testing after modification was performed with etomidate plus low GABA (combined efficacy about 5% of maximum) and etomidate plus 1 mM GABA. In most experiments, modification exposures to pCMBS of 5-10s each were performed, followed by at least two minutes of wash for pCMBS alone and longer washes (5 to 10 min) when GABA and/or etomidate was present. Up to ten modification and post-test cycles were performed on each oocyte. The ratio of low GABA vs. high GABA current responses was calculated, and all ratios were normalized to the control ratio before pCMBS exposure.
Normalized response ratios were plotted as a function of total pCMBS exposure (seconds or seconds × [pCMBS]). For some data sets, exponential time constants were derived from single This article has not been copyedited and formatted. The final version may differ from this version. were stimulated using pulses of GABA delivered via a quad (2 × 2) superfusion pipette coupled to piezo-electric elements that switched superfusion solutions in under 1 ms. Currents were filtered at 5 kHz and digitized at 10 kHz for off-line analysis.
Data Analysis: Quantitative analyses of agonist concentration-responses, etomidate-induced left shift, and allosteric co-agonist model fitting followed our approach described elsewhere (Desai et al., 2009; Stewart et al., 2008 
Eq. 2
This article has not been copyedited and formatted. The final version may differ from this version. Analysis of patch macrocurrents for activation, desensitization, and deactivation kinetics was performed as described in Scheller & Forman (2002) using non-linear least squares fits to Eq. 4
and F-tests at P = 0.99 (Clampfit8.0; Molecular Devices) to choose the best number of exponents:
Activation traces were fitted best with a single exponent, while desensitization and deactivation were fitted best with two exponents.
Statistical Analysis:
Results are reported as mean ± standard deviation. Nonlinear regression errors are those from fits in Origin 6.1 (OriginLab), GraphPad Prism 5.02 (Graphpad, This article has not been copyedited and formatted. The final version may differ from this version. to three-fold. This is a significantly smaller leftward-shift ratio than that observed in α1β2γ2L
receptors in the presence of 3.2 μM etomidate (Table 1) .
Etomidate at up to 1 mM elicited no significant direct activation of α1β2M286Cγ2L receptors (< 1.5% of maximal GABA currents; Fig 1D) . We also studied etomidate-dependent modulation of low GABA (20 μM ≈ EC 3 ) currents. Modulation of low GABA responses was characterized by an etomidate EC 50 of 24 μM and maximal enhancement at an etomidate concentration of 100 μM resulted in current responses averaging about 70% of maximal GABA currents ( Fig 1D) .
Rapid superfusion and patch-clamp electrophysiology was used to study macro-current kinetics of α1β2M286Cγ2L receptors. Rapid application of 10 mM GABA to outside-out membrane patches from HEK293 cells expressing α1β2M286Cγ2L receptors resulted in currents with kinetic properties similar to those recorded with wild-type receptors ( Fig 1E , Table   1 ). The maximal current activation rate was approximately 3000 s -1 , desensitization proceeds with two rates, and deactivation also displayed two distinct rates. Based on previously published experiments, the basal gating parameter, L 0 , for wild-type α1β2γ2L is estimated to be around 25,000 (Desai et al., 2009; Rüsch et al., 2004) . In doublemutant α1L264Tβ2M286Cγ2L receptors, picrotoxin-sensitive spontaneous activity averaged 3%
of the maximal GABA-activated currents (Fig 2D) . In comparison, oocyte-expressed α1L264Tβ2γ2L receptors display about 10% spontaneous activation (Desai et al., 2009; Rüsch et al., 2004) . Assuming that the basal gating effects of α1L264T and β2M286C are independent, the β2M286C mutation reduces spontaneous activation around three-fold, so we set the value of L 0 for α1β2M286Cγ2L receptors in global analysis at 75,000, three times that of wild-type. (Fig 3) . Receptors exposed to pCMBS developed larger current responses to low GABA concentrations (30 μM, approx EC 5 ) relative to high GABA concentrations (1-2 mM).
Exposure to 50 μM pCMBS in the absence of GABA (inactive receptors) resulted in I 30μM /I 2mM increasing to about double its baseline value (Fig 3A, B ) in 60 to 80 seconds. Exponential fits to normalized I 30μM /I 2mM as a function of pCMBS exposure time indicated modification rates averaging 1000 ± 470 M -1 s -1 (mean ± SD, n = 4). When receptors were exposed to pCMBS coapplied with 2 mM GABA, the apparent rate of receptor modification increased (Fig 3C, D) .
Exponential fits indicated rates of 1800 ± 580 M -1 s -1 (mean ± SD, n = 4). In addition, the amplitude of the pCMBS-induced gating effect was consistently larger when GABA was present (averaging six-fold enhancement above baseline).
To examine the impact of GABA in more detail, we performed experiments where α1β2M286Cγ2L receptors were first modified with 50 μM pCMBS in the absence of GABA, then exposed to GABA + pCMBS. These studies reveal that addition of GABA to pCMBS increases the response to low GABA (I 30μM ; Fig 3E, triangles) beyond that observed after pCMBS alone.
Moreover, the pCMBS-induced response to high GABA (I 2mM ; Fig 3E, diamonds) drops far more following GABA + pCMBS exposure than with pCMBS alone. Together these effects combine to increase the I 30μM /I 2mM ratio when GABA is present beyond the level achieved with pCMBS alone (Fig 3F) . Exposure to higher (250-500 μM) pCMBS also resulted in higher (three to fourfold) I 30μM /I 2mM ratios (data not shown). These results suggest that partial modification of β2M286C was achieved with 50 μM pCMBS alone, and that modification in the presence of GABA results in accumulation of deeply desensitized receptors that did not re-activate on the timescale of our experiments.
This article has not been copyedited and formatted. The final version may differ from this version. Because GABA affected the change in amplitude of I 30μM /I 2mM after pCMBS more than the apparent exponential rate change, we adopted an alternative approach to estimating initial rates of pCMBS modification, using linear slope analysis. Slope analyses resulted in average initial modification rates of around 400 M -1 s -1 in the absence of GABA and 11000 M -1 s -1 in the presence of GABA. This suggests that GABA activation increases pCMBS modification rates over 20-fold, a much larger ratio than that based on exponential rate analysis (1.8-fold).
Control experiments in α1β2γ2L receptors exposed to pCMBS (up to 2 mM for 60 s) failed to demonstrate significant (> 10%) functional change in electrophysiological responses to zero, low or high GABA (data not shown).
Etomidate protection at α1β2M286Cγ2L receptors
For etomidate protection experiments, receptors were equilibrated with etomidate before and during pCMBS modification and post-modification functional testing. Because etomidate enhances responses to low GABA more than high GABA, we reduced the low GABA concentration used for post-modification testing (1-10 μM) to produce about 5% maximal response in the presence of etomidate. Initial modification rates were quantified from linear fits to normalized I loGABA /I 1-2mM ratios after two or three pCMBS exposures.
In the absence of GABA, initial slope analysis resulted in an apparent β2M286C modification rate of 400 ± 96 M -1 s -1 (Fig. 4A, red squares) . Addition of 300 μM etomidate completely inhibited pCMBS modification (initial slope < 0; Fig 4A, brown diamonds) . We also measured the initial rate of pCMBS modification at β2M286C in the presence of etomidate concentrations ranging from 3 to 100 μM. Data for 3 μM and 30 μM etomidate are shown in Fig. 4A . The modification rate vs.
[etomidate] data were fit by non-linear least-squares to a logistic function with nH = 1, resulting in an estimate of 14 μM for the 50% protecting concentration (PC 50 ; Fig.   4B ).
This article has not been copyedited and formatted. The final version may differ from this version. In the presence of GABA (2 mM), initial slope analysis revealed an apparent β2M286C modification rate of 11,300 ± 2000 M -1 s -1 (Fig 4C, red squares) . Addition of alphaxalone (2 μM)
to GABA further increased the apparent initial rate of β2M286C modification to 16,600 ± 4000 M -1 s -1 (Fig 4C, green half-filled hexagons) . In contrast, addition of etomidate (range 1 to 300 μM) reduced initial rates of GABA-activated α1β2M286Cγ2L receptor modification by pCMBS. Figure 4C displays data in the presence of 3, 30, and 300 μM etomidate. Logistic analysis of modification rates using the control with GABA alone results in a fitted etomidate PC 50 value of 2.2 μM for GABA-activated receptors (Fig. 4D, solid results in a leftward shift of the logistic fit, with PC 50 = 1.1 μM (Fig 4D, dashed black 
line).
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Interestingly, some functional effects of the β2M286C mutation are opposite of those seen with the β2M286W mutation, which increases spontaneous activation, and sensitizes receptors to agonism by GABA (Stewart et al., 2008) . However, both tryptophan and cysteine mutations at β2M286 reduce etomidate modulation and etomidate direct activation in comparison to wild-type. Investigation of various βM286 mutations demonstrated that sidechain volume may be an important determinant of propofol effects (Krasowski et al., 2001 ). Our results show that the βM286 side-chain influences both anesthetic binding and basal channel gating, and that the magnitude and directions of these effects are independent.
As previously reported for rat GABA A receptors (Bali and Akabas, 2004; Bali et al., 2009), we found that in human receptors, β2M286C is accessible to the water-soluble reagent pCMBS.
This article has not been copyedited and formatted. The final version may differ from this version. cannot definitively conclude that the β2M286 sidechain is within the etomidate binding pocket, rather than just near it. An alternative mechanism is that etomidate blocks the aqueous pathway for pCMBS access. Bali and Akabas (2004) found that propofol also protects βM286C from modification in GABA-activated receptors. Propofol also inhibits azi-etomidate photolabeling (Li et al., 2010) , although not completely. The most parsimonious interpretation is that both propofol and etomidate have partially overlapping binding sites that abut β2M286.
Etomidate occupancy of its sites, inferred from protection of β2M286C from pCMBS modification, is dependent on both the concentration of etomidate and on the receptor state.
The PC 50 for etomidate protection in the resting state is 14 μM (Fig 4B) needed. Moreover, the fraction of desensitized receptors when GABA is absent is unknown and cannot be determined from functional studies, but the close match between K E from functional modeling and PC 50 in inactive receptors suggests that at most a small fraction of channels are in high-affinity states.
While thorough characterization of GABA and etomidate-dependent receptor activity provided us with a mechanistic framework to interpret multiple effects of the β2M286C mutation, the major factor influencing design and interpretation of SCAM protection experiments was the absence of etomidate agonism. Indeed, allosteric principles imply generally that in SCAM protection studies using ligands with agonist activity, the presence or absence of significant agonism in cysteine substituted mutant channels determines the conditions under which protection may be tested. In mutant channels that, like wild-type GABA Table 1 .
This article has not been copyedited and formatted. The final version may differ from this version. alphaxalone control: Max = 16600 ± 890 M -1 s -1 and PC 50 = 1.1 μM (95% CI = 0.65 to 1.9 μM).
The red solid line represents a theoretical protection profile calculated using the fitted MWC model parameters for α1β2M286Cγ2L (Table 1) . Open probability was calculated as a function of [etomidate] at GABA = 2mM, protection was calculated using the predicted open-state etomidate dissociation constant (K E × d ≈ 1.4 μM) and a Hill slope of 1.0, and control modification rate was set at the experimentally observed value (11,300 M -1 s -1 ).
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